SARS-CoV-2

[Cell Reports] Investigators screened B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern identified to date.

[Cell Reports] Scientists showed that critical COVID-19 was associated with enhanced eosinophil-mediated inflammation when compared to non-critical cases.

[Science] Immunoglobulin G from mRNA-immunized nonhuman primates was passively transferred in a highly pathogenic Syrian hamster SARS-CoV-2 challenge model to determine whether these antibodies were sufficient for protection.

[Nature Reviews Microbiology] The authors delineate the structural features of SARS-CoV-2 from the whole viral particle to the individual viral proteins and discuss their functions as well as their potential as targets for therapeutic interventions.

[Nature Communications] To discern which host factors were reliable anti-coronavirus therapeutic targets, investigators generated mutant clonal IOs for 19 host genes previously implicated in coronavirus biology.

[Molecular Medicine] Researchers used a data-driven approach, combining results from the screening of a large transcriptomic database and molecular docking analyses, with in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19.